Standort: ---
Exemplare:
---
| Online-Ressource |
Verfasst von: | Vay, Manuela [VerfasserIn]  |
| Meyer, Marleen J. [VerfasserIn]  |
| Blank, Antje [VerfasserIn]  |
| Skopp, Gisela [VerfasserIn]  |
| Rose, Peter [VerfasserIn]  |
| Tzvetkov, Mladen Vassilev [VerfasserIn]  |
| Mikus, Gerd [VerfasserIn]  |
Titel: | Oral yohimbine as a new probe drug to predict CYP2D6 activity |
Titelzusatz: | results of a fixed-sequence phase I trial |
Verf.angabe: | Manuela Vay, Marleen Julia Meyer, Antje Blank, Gisela Skopp, Peter Rose, Mladen Vassilev Tzvetkov, Gerd Mikus |
E-Jahr: | 2020 |
Jahr: | 15 February 2020 |
Umfang: | 13 S. |
Fussnoten: | Gesehen am 12.08.2021 |
Titel Quelle: | Enthalten in: Clinical pharmacokinetics |
Ort Quelle: | Berlin [u.a.] : Springer, 1976 |
Jahr Quelle: | 2020 |
Band/Heft Quelle: | 59(2020), 7, Seite 927-939 |
ISSN Quelle: | 1179-1926 |
Abstract: | Yohimbine pharmacokinetics were determined after oral administration of a single oral dose of yohimbine 5 mg and a microdose of yohimbine 50 µg in relation to different cytochrome P450 (CYP) 2D6 genotypes. The CYP2D6 inhibitor paroxetine was used to investigate the influence on yohimbine pharmacokinetics. Microdosed midazolam was applied to evaluate a possible impact of yohimbine on CYP3A activity and the possibility of combining microdosed yohimbine and midazolam to simultaneously determine CYP2D6 and CYP3A activity. |
DOI: | doi:10.1007/s40262-020-00862-6 |
URL: | kostenfrei: Volltext: https://doi.org/10.1007/s40262-020-00862-6 |
| DOI: https://doi.org/10.1007/s40262-020-00862-6 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1766552552 |
Verknüpfungen: | → Zeitschrift |
|
|
| |
Lokale URL UB: | Zum Volltext |
Oral yohimbine as a new probe drug to predict CYP2D6 activity / Vay, Manuela [VerfasserIn]; 15 February 2020 (Online-Ressource)
68770216